The state-of-the-art development will be located near Glasgow Airport and will be led by CPI in partnership with The University of Strathclyde, Scottish Enterprise, and founding industry partners, AstraZeneca and GlaxoSmithKline.
It is said that the centre will ensure the UK is a technology and innovation leader in small molecule pharmaceutical and fine chemical manufacturing, thereby boosting the competitiveness of both sectors.
Cameron Stewart, Regional Director at Interserve Construction said: “The new centre at Inchinnan is a really exciting, innovative project where our strengths in the medical sector will hugely benefit the project.
“We will bring our considerable experience and capabilities in delivering similar projects like the National Biologics Manufacturing Centre for CPI in Darlington, which is currently supporting efforts to manufacture and formulate vaccines for COVID-19, and the Jack Copeland Centre in Edinburgh for the Scottish National Blood Transfusion Service. The Medicines Manufacturing Innovation Centre will be market leading for the pharmaceutical industry and we are delighted that will be part of that.”
Nigel Perry, Chief Executive Officer at CPI, said: “The Medicines Manufacturing Innovation Centre will enhance the UK’s existing competitive advantage by deepening the skills base and strengthening the rationale for companies to invest in new, highly productive medicines manufacturing.”
Scottish Government Minister for Business, Innovation and Energy, Paul Wheelhouse, said: “I am delighted that the Medicines Manufacturing Innovation Centre will be located in Scotland, given its potential to become a global centre of excellence and bringing significant benefits to Scotland’s economy.”